Pierre Fabre Laboratories Selects QUMAS DocCompliance to Manage
Quality Documents Across Entire Organization
CORK, IRELAND--(Marketwired - Apr 28, 2014) - QUMAS, an Accelrys
company (NASDAQ: ACCL), today announced that Pierre Fabre
Laboratories, a leading pharmaceutical and cosmetics company with
headquarters in Castres, France, has selected QUMAS DocCompliance
to manage and control quality documents across the entire company.
The QUMAS Compliance Platform was selected after an extensive
evaluation process conducted by members of the Quality Assurance
and IT teams at Pierre Fabre Laboratories. The QUMAS solution will
be rolled out to 3,850 Pierre Fabre employees initially.
QUMAS DocCompliance provides Pierre Fabre Laboratories with a
complete web-based electronic document management system that
enables users to create, manage, circulate and securely store all
documents and content related to quality assurance and quality
control across the company's product portfolio. The platform fully
supports Electronic Signatures as per the FDA 21 CFR Part 11
requirements and is configurable, allowing companies to mirror
their organizational structures and practices. All of the
compliance capabilities of the platform are accessed through
MyQUMAS, a user-friendly web-based interface.
"QUMAS provides Pierre Fabre with a scalable solution that will
enable employees across all of its product sites to collaborate on
quality assurance content and documents in a controlled, compliant
and fully auditable manner," stated Kevin O'Leary, CEO for QUMAS.
"We are delighted to be adding another leading French company to
our client list, and plan to increase our client base in Europe
significantly this year."
"We conducted a very thorough evaluation of a number of vendor
solutions," commented Pierre Contreras, business project director
for Pierre Fabre Laboratories. "We were very impressed with the
advanced features of DocCompliance and its large reference base of
companies across our industry, as well as the professionalism and
responsiveness of the QUMAS team."
About QUMAS
QUMAS is the leader in Enterprise Compliance Solutions with more
than 270 global customer deployments and two decades of experience
helping companies in highly regulated industries. QUMAS is a Gold
Microsoft Partner, and provides the QUMAS Compliance Platform on
SharePoint 2010, Documentum, Oracle or SQL. For more information,
visit www.qumas.com.
About Accelrys
QUMAS is an Accelrys company. Accelrys (NASDAQ: ACCL), a leading
provider of scientific innovation lifecycle management software,
supports industries and organizations that rely on scientific
innovation to differentiate themselves. The industry-leading
Accelrys Enterprise Platform provides a broad, flexible scientific
foundation optimized to integrate the diversity of science,
experimental processes and information requirements across the
research, development, QA/QC and manufacturing phases of product
development. Accelrys offers capabilities in scientific data
management, modeling and simulation, research informatics,
laboratory informatics, enterprise quality management,
environmental health & safety and operations intelligence for
customers in science-driven industries. Using Accelrys technology,
scientific innovators can access, organize, analyze and share data
in unprecedented ways across the research, laboratory and
manufacturing continuum, ultimately enhancing innovation, improving
productivity and compliance, reducing costs and accelerating
product development from research to manufacturing.
Accelrys solutions are used by more than 2,000 customers in the
pharmaceutical, biotechnology, energy, chemicals, aerospace,
consumer packaged goods and industrial products industries.
Headquartered in San Diego, Calif., Accelrys employs approximately
225 full-time PhD scientists. For more information about Accelrys,
visit www.accelrys.com.
About Pierre Fabre Laboratories
Pierre Fabre is the 3rd largest French pharmaceutical group. In
2013, its sales reached EUR 2.008 Billion, with international
revenues accounting for 56%. Founded and still based in the
South-west of France, Pierre Fabre currently has branches in 44
countries and distribution agreements in over 130 countries.
Covering all aspects of healthcare, from prescription drugs and
OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ
over 10,000 people worldwide. Every year, the group allocates more
than 17% of its drug revenues to R&D, focusing on three main
areas: oncology, dermatology and neuropsychiatry.
With brands such as Avène, Klorane, Ducray, René Furterer,
A-Derma, Galénic, Naturactive, Elgydium, Eludril or Drill, Pierre
Fabre Laboratories are market leaders when it comes to skin, hair
and oral care products sold in French pharmacy channels. Avène is
marketed worldwide, and is the leading dermo-cosmetics brand in
Europe, Japan and China. In oncology, Pierre Fabre achieves 90% of
its revenues outside of its home country.
Through the Pierre Fabre Participations holding company, the
Pierre Fabre Foundation, a government-recognized public-interest
foundation, owns 86% of Pierre Fabre Laboratories. 7% of remaining
shares are owned by company employees, and 7% are treasury
stock.
The French certification group AFNOR has audited Pierre Fabre
Laboratories for its corporate social responsibility (CSR)
performance at advanced level (AFAQ 26 000)
To find out more, please visit www.pierre-fabre.com.
All trade names, trademarks, and service marks are rightful
property of their respective owners.
MEDIA CONTACT: Caoimhe Kiely VP Marketing QUMAS +353 21 4915100 Email
Contact www.qumas.com
Accelrys, Inc. (MM) (NASDAQ:ACCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accelrys, Inc. (MM) (NASDAQ:ACCL)
Historical Stock Chart
From Sep 2023 to Sep 2024